Coeptis Therapeutics (NASDAQ:COEP) Trading Down 19.7% – Here’s What Happened

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was down 19.7% on Thursday . The company traded as low as $10.49 and last traded at $10.61. Approximately 150,093 shares were traded during trading, an increase of 163% from the average daily volume of 57,040 shares. The stock had previously closed at $13.21.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Coeptis Therapeutics in a research note on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Coeptis Therapeutics Trading Down 19.7%

The company has a debt-to-equity ratio of 0.01, a current ratio of 2.21 and a quick ratio of 2.21. The business has a fifty day moving average of $14.55 and a 200-day moving average of $14.30. The stock has a market capitalization of $56.66 million, a price-to-earnings ratio of -3.71 and a beta of -0.50.

Coeptis Therapeutics (NASDAQ:COEP) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.58) earnings per share for the quarter. The firm had revenue of $0.24 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Coeptis Therapeutics stock. Yorkville Advisors Global LP acquired a new stake in shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 8,000 shares of the company’s stock, valued at approximately $140,000. Coeptis Therapeutics comprises about 0.0% of Yorkville Advisors Global LP’s portfolio, making the stock its 24th largest holding. Yorkville Advisors Global LP owned about 0.17% of Coeptis Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 13.88% of the company’s stock.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.